Page 133 - 73_04

VOL. 73 (4), 927-945, 2007 DERIVADOS DE 1,4-DI-N-ÓXIDO DE QUINOXALINA...

(11) KER, A. J.; CLARKE, E. D. Y GREENHOW, D. T. (1995) Hypoxia-Selective Agents
(12) Derived from Quinoxaline 1,4-Di-N-Oxides. J. Med. Chem. 38: 1786-1792.
AZQUETA, A.; PACHON, G.; CASCANTE, M.; CREPPY, E. E.; MONGE, A. Y DE CERAIN,
(13) A. L. (2005) Selective toxicity of a quinoxaline 1,4-di-N-oxide derivative in
(14) human tumour cell lines. Arzneim.-Forsch. 55: 177-182.
(15) AZQUETA, A.; PACHON, G.; CASCANTE, M.; CREPPY, E. E. Y DE CERAIN, A. L. (2005)
DNA damage induced by a quinoxaline 1,4-di-N-oxide derivative (hypoxic
(16) selective agent) in Caco-2 cells evaluated by the comet assay. Mutagenesis.
20: 165-171.
(17) CHOWDHURY, G.; KOTANDENIYA, D.; DANIELS, J. S.; BARNES, C. L. Y GATES, K. S.
(2004) Enzyme-activated, hypoxia-selective DNA damage by 3-amino-2-qui-
(18) noxalinecarbonitrile 1,4-di-N-oxide. Chem. Res. Toxicol. 17: 1399-1405.
(19) GANLEY, B.; CHOWDHURY, G.; BHANSALI, J.; DANIELS, J. S. Y GATES, K. S. (2001)
(20) Redox-activated, hypoxia-selective DNA cleavage by quinoxaline 1,4-di-N-
(21) oxide. Bioorg. Med. Chem. 9: 2395-2401.
(22) AGUIRRE, G.; CERECETTO, H.; DI MAIO, R.; GONZALEZ, M.; ALFARO, M. E. M.; JASO,
(23) A.; ZARRANZ, B.; ORTEGA, M. A.; ALDANA, I. Y MONGE-VEGA, A. (2004) Quinoxa-
line NN ‘-dioxide derivatives and related compounds as growth inhibitors of
Trypanosoma cruzi. Structure-activity YP relationships. Bioorg. Med. Chem.
Lett. 14: 3835-3839.
URQUIOLA, C.; VIEITES, M.; AGUIRRE, G.; MARIN, A.; SOLANO, B.; ARRAMBIDE, G.;
NOBLIA, P.; LAVAGGI, M. L.; TORRE, M. H.; GONZALEZ, M.; MONGE, A.; GAMBINO,
D. Y CERECETTO, H. (2006) Improving anti-trypanosomal activity of 3-amino-
quinoxaline-2-carbonitrile N-1,N-4-dioxide derivatives by complexation with
vanadium. Bioorg. Med. Chem. 14: 5503-5509.
CARTA, A.; LORIGA, M.; PAGLIETTI, G.; MATTANA, A.; FIORI, P. L.; MOLLICOTTI, P.;
SECHI, L. Y ZANETTI, S. (2004) Synthesis, anti-mycobacterial, anti-trichomonas
and anti-candida in vitro activities of 2-substituted-6,7-difluoro-3-methylqui-
noxaline 1,4-dioxides. Eur. J. Med. Chem. 39: 195-203.
BROWN, D. J. (2004) Quinoxalines. Supplement II. Wiley & Sons. New York.
CARTA, A.; CORONA, P. Y LORIGA, M. (2005) Quinoxaline 1,4-dioxide: A ver-
satile scaffold endowed with manifold activities. Curr. Med. Chem. 12: 2259-
2272.
MONTOYA, M. E.; SAINZ, Y.; ORTEGA, M. A.; DE CERAIN, A. L. Y MONGE, A. (1998)
Synthesis and antituberculosis activity of some new 2-quinoxalinecarbonitri-
les. Farmaco. 53: 570-573.
ORTEGA, M. A.; SAINZ, Y.; MONTOYA, M. E.; DE CERAIN, A. L. Y MONGE, A. (1999)
Synthesis and antituberculosis activity of new 2-quinoxalinecarbonitrile 1,4-
di-N-oxides. Pharmazie. 54: 24-25.
SAINZ, Y.; MONTOYA, M. E.; MARTINEZ-CRESPO, F. J.; ORTEGA, M. A.; DE CERAIN, A.
L. Y MONGE, A. (1999) New quinoxaline 1,4-di-N-oxides for treatment of tu-
berculosis. Arzneim.-Forsch. 49: 55-59.
SANNA, P.; CARTA, A.; LORIGA, M.; ZANETTI, S. Y SECHI, L. (1999) Preparation and
biological evaluation of 6/7-trifluoromethyl(nitro)-, 6,7-difluoro-3-alkyl (aryl)-
substituted-quinoxalin-2-ones. Part 3. Farmaco. 54: 169-177.

943